THC FARMACEUTICALS WELCOMES JORDAN DESPANIE, PhD TO ITS ADVISORY BOARD.
15 Mai 2019 - 9:33PM
InvestorsHub NewsWire
THC FARMACEUTICALS WELCOMES JORDAN
DESPANIE, PhD TO ITS ADVISORY BOARD.
Thousand Oaks, CA -- May 15, 2019 -- InvestorsHub
NewsWire -- CBDual Biotechnology Corp., a subsidiary of THC
Farmaceuticals, Inc. (OTC
PINK: CBDG) is pleased to announce the appointment of Jordan
Despanie, PhD to its Advisory Board. Bringing over a
decade of research experience, Dr. Despanie completed his
Pharmaceutical Sciences PhD at the University of Southern
California following a BS in Biology from Louisiana State
University.
Dr. Despanie began his biomedical career at LSU investigating
molecular therapies such as oncolytic virotherapy and antiviral
gene silencing before joining Johns Hopkins Hospital to probe how
defective protein trafficking contributes to cystic fibrosis.
His dissertation, “Tubulin-based fusion proteins as multifunctional
tools”, detailing a novel class of chemotherapy nanomedicines to
combat triple-negative breast cancers (an aggressive disease
subtype for which there are currently no targeted treatments)
received over $178,000 in NIH grant
funding.
In 2014,
Dr. Despanie also founded S-aima Biopharmaceutics LLC, a biotech
startup which sought to develop an artificial blood nanomedicine
for temporary blood replacement on the battlefield and during
civilian emergencies.
An enthusiastic Dr. Despanie affirms, “This is a unique opportunity
to leverage my passion for nanomedicine towards designing CBD
formulations that will undoubtedly grant us a competitive edge in
the marketplace.”
“We are
thrilled and honored to have Dr. Jordan Despanie join CBDG. We look
forward to working with him as we take CBDG’s science to the next
level”, says Mike Gravel, Chairman and CEO of THC Farmaceuticals,
Inc.
About CBDual
Biotechnology
CBDual Biotechnology Corp. is owned by THC
Farmacuticals, a publicly traded company
(OTC:
CBDG), which is a biotechnology company with propriety
technology for enhanced oral delivery methods. This technology for
enhanced oral delivery of bioactive cannabinoids and other delivery
methods. This technology promotes overall oral health due to higher
effectiveness of the delivery methodology. The company was founded
in 2016 and is headquartered in California, with its R &D in
the US and Israel.
For
additional information visit the company's
website: www.cbdual.com and
www.cbdg.com
Follow us
on Twitter: @CBDualBiotech and @THCFarma
Forward-Looking Statements:
This press
release contains "forward-looking statements." Although the
forward-looking statements in this release reflect the good faith
judgment of management, forward-looking statements are inherently
subject to known and unknown risks and uncertainties that may cause
actual results to be materially different from those discussed in
these forward-looking statements. Readers are urged to carefully
review and consider the various disclosures made by us in our
reports filed with the Securities and Exchange Commission,
including the risk factors that attempt to advise interested
parties of the risks that may affect our business, financial
condition, results of operation and cash flows. If one or more of
these risks or uncertainties materialize, or if the underlying
assumptions prove incorrect, our actual results may vary materially
from those expected or projected. Readers are urged not to place
undue reliance on these forward-looking statements, which speak
only as of the date of this release. We assume no obligation to
update any forward-looking statements in order to reflect any event
or circumstance that may arise after the date of this
release.
THC Farmaceuticals (PK) (USOTC:CBDG)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
THC Farmaceuticals (PK) (USOTC:CBDG)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024